<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04412577</url>
  </required_header>
  <id_info>
    <org_study_id>TQB3473-I-01</org_study_id>
    <nct_id>NCT04412577</nct_id>
  </id_info>
  <brief_title>A Study of TQB3473 Tablets in Subjects With Relapsed or Refractory Hematological Malignancies</brief_title>
  <official_title>A Phase I, Open-label, Dose Escalation and Expansion Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3473 Tablets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the maximum tolerated dose (MTD), occurrence of all adverse
      events (AE) and serious adverse events (SAE) , pharmacokinetic parameters and antitumor
      effect of TQB3473 tablets in Chinese adult patients with Relapsed or refractory hematological
      malignancies.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>up to 31 days</time_frame>
    <description>MTD was defined as the dose in which more than 2 of up to 6 patients developed a DLT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>30minutes, 1hour, 2hour, 4hour, 6hour, 8hour,12hour, 24hour, 48hour post-dose on day 1 and day 31; 30minutes pre-dose on day 1, day 4, day 11,day 18 ,day 25 and day 31.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax Cmax</measure>
    <time_frame>30minutes, 1hour, 2hour, 4hour, 6hour, 8hour,12hour, 24hour, 48hour post-dose on day 1 and day 31; 30minutes pre-dose on day 1, day 4, day 11,day 18 ,day 25 and day 31.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>30minutes, 1hour, 2hour, 4hour, 6hour, 8hour,12hour, 24hour, 48hour post-dose on day 1 and day 31; 30minutes pre-dose on day 1, day 4, day 11,day 18 ,day 25 and day 31.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>up to 96 weeks</time_frame>
    <description>Percentage of subjects achieving complete response (CR) and partial response (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>up to 96 weeks</time_frame>
    <description>PFS defined as the time from first dose to the first documented progressive disease (PD) or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>up to 96 weeks</time_frame>
    <description>DOR defined as time from earliest date of disease response to earliest date of disease progression based on radiographic assessment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">57</enrollment>
  <condition>Relapsed/Refractory Hematological Malignancies</condition>
  <arm_group>
    <arm_group_label>TQB3473 tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TQB3473 tablets administered once daily in 28-day cycle .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQB3473</intervention_name>
    <description>TQB3473 tablets administered orally once. Then TQB3473 tablets administered orally, once daily in 28-day cycle after 3 days of first administration.</description>
    <arm_group_label>TQB3473 tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -1.Understood and signed an informed consent form. 2. Relapsed or refractory malignant
        hematological tumors. 3. Eastern Cooperative Oncology Group (ECOG) performance status score
        of 0 to 1; Life expectancy ≥12 weeks.

        4. Has at least one measurable lesion. 5. Adequate organ system function. 6. Patients need
        to adopt effective methods of contraception.

        Exclusion Criteria:

          -  1. Severe hypersensitivity to the drug or ingredients. 2. Has received chemotherapy,
             radiotherapy, immunotherapy or any other anti-tumor therapy within 14 days before the
             first dose.

             3. Has received spleen tyrosine kinase (SYK) inhibitors. 4. Has to use ≥ 10 mg/day
             glucocorticoid prednisone. 5. Has received BTK inhibitors and PI3K inhibitors before
             the first dose. 6. Has received allogeneic hematopoietic stem cell transplantation. 7.
             Has received autologous hematopoietic stem cell transplantation within 12 weeks before
             the first dose.

             8. Has any acute or chronic gastrointestinal diseases. 9. Has primary central nervous
             system lymphoma, or brain metastases with clinical symptoms, spinal cord compression,
             cancerous meningitis.

             10. Intermediate-risk or high-risk myelodysplastic syndrome. 11. Pregnancy and
             lactation women. 12. Has any serious and/or uncontrollable disease. 13. Has active
             autoimmune disease and received immunosuppressive therapy. 14. Has a history of
             neurological or mental disorders. 15. Has uncontrollable systemic bacterial, fungal or
             viral active infections 16. The toxicity of previous antitumor treatment is not
             recovered to ≤ grade 1. 17. Has other malignancies. 18. Has received surgery within 4
             weeks before the first administration. 19. Has participated in any other clinical
             trials. 20. According to the judgement of the investigators, there are other factors
             that may lead to the termination of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Peng Liu, Doctor</last_name>
    <phone>021-60267405</phone>
    <email>Liu.peng@zs-hospital.sh.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yongping Song, Doctor</last_name>
      <email>songyongping@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Yongping Song, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Peng Liu, Doctor</last_name>
      <phone>021-60267405</phone>
      <email>Liu.peng@zs-hospital.sh.cn</email>
    </contact>
    <investigator>
      <last_name>Peng Liu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 28, 2020</study_first_submitted>
  <study_first_submitted_qc>May 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2020</study_first_posted>
  <last_update_submitted>May 28, 2020</last_update_submitted>
  <last_update_submitted_qc>May 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

